SCHEMBL5237223

SCHEMBL5237223

O=C1[C@H](Cc2ccc(Cl)c(Cl)c2)N(Cc2ccccn2)C(=O)CCN1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.39
▸ HDAC8 Q9BY41 2/20 0.39
▸ HDAC6 Q9UBN7 2/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ CACNA1B Q00975 1/20 0.39
▸ P2RX7 Q99572 2/20 0.38
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ TACR1 P25103 5/20 0.37
▸ OPRM1 P35372 1/20 0.36
▸ OPRD1 P41143 1/20 0.36
▸ OPRK1 P41145 1/20 0.36
▸ WDR5 P61964 2/20 0.35
▸ SRPK1 Q96SB4 2/20 0.35
▸ ADRB2 P07550 1/20 0.35
▸ FPR1 P21462 1/20 0.35
▸ GPR183 P32249 1/20 0.35
▸ APLNR P35414 1/20 0.35
▸ GLP1R P43220 1/20 0.35
▸ GPBAR1 Q8TDU6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5234199 0.87 WDR5 (0.37) HDAC1HDAC8HDAC6P2RX7TACR1
SCHEMBL5234192 0.87 WDR5 (0.37) HDAC1HDAC8HDAC6P2RX7TACR1
SCHEMBL5234746 0.85 TACR1 (0.33) TACR1WDR5
SCHEMBL5235531 0.85 MAPT (0.42) HDAC1HDAC8HDAC6HDAC2P2RX7
SCHEMBL5235528 0.85 MAPT (0.42) HDAC1HDAC8HDAC6HDAC2P2RX7
SCHEMBL5229738 0.80 CNR2 (0.38) TACR1
SCHEMBL5235425 0.75 TACR1 (0.37) TACR1
SCHEMBL5235420 0.75 TACR1 (0.37) TACR1
SCHEMBL5232486 0.75 WDR5 (0.35) TACR1WDR5SIRT2SIRT1
SCHEMBL5229625 0.72 TACR1 (0.48) HDAC1HDAC8HDAC6TACR1WDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US claimed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US claimed
EP-1296961-B1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-02-14 — — EP disclosed
EP-1296961-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-02 — — EP disclosed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US disclosed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US disclosed
WO-2001090083-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation BDKRB2, NPSR1, BDKRB1 HDAC1 530/4885HDAC8 752/4885HDAC6 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback